P2X7 receptor-mediated analgesia in cancer-induced bone pain

Neuroscience

Volumn 291, Issue , 2015, Pages 93-105

  Falk, S ^a   Schwab, S D ^a   Frosig Jorgensen M ^a   Clausen, R P ^a   Dickenson, A H ^b   Heegaard, A M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Analgesia; Cancer induced bone pain; Neuronal responses; P2X7R antagonism; Pain behavior

Indexed keywords

A 839977; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; A-839977; ANALGESIC AGENT; PURINERGIC P2X RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE PAIN; CANCER INDUCED BONE PAIN; CONTROLLED STUDY; ELECTROSTIMULATION; EVOKED RESPONSE; IN VIVO STUDY; MECHANICAL STIMULATION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT MODEL; SHAM PROCEDURE; SPINAL CORD DORSAL HORN; THERMAL STIMULATION; ANIMAL; BONE TUMOR; CANCER TRANSPLANTATION; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; MALE; METABOLISM; MOTOR ACTIVITY; PAGET NIPPLE DISEASE; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTERIOR HORN CELL; SPRAGUE DAWLEY RAT; SYNTHESIS; TUMOR CELL LINE;

ANALGESICS, NON-NARCOTIC; ANIMALS; BONE NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAMMARY NEOPLASMS, ANIMAL; MOTOR ACTIVITY; NEOPLASM TRANSPLANTATION; PAIN; POSTERIOR HORN CELLS; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2X7; TETRAZOLES;

EID: 84923348598     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.02.011     Document Type: Article

References (46)

1. Adinolfi E., Amoroso F., Giuliani A.L. P2X7 receptor function in bone-related cancer. J Osteoporos 2012, 2012:1-10.
2. Adinolfi E., Raffaghello L., Giuliani A.L., Cavazzini L., Capece M., Chiozzi P., Bianchi G., Kroemer G., Pistoia V., Di Virgilio F. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 2012, 72:2957-2969.
3. Alves L.A., de Melo Reis R.A., de Souza C.A., de Freitas M.S., Teixeira P.C., Neto Moreira Ferreira D., Xavier R.F. The P2X7 receptor: shifting from a low- to a high-conductance channel - An enigmatic phenomenon?. Biochim Biophys Acta 2014, 1838:2578-2587.
4. Burnstock G. Purinergic mechanisms and pain - An update. Eur J Pharmacol 2013, 716:24-40.
5. Caraceni A., Portenoy R.K. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999, 82:263-274.
6. Chessell I.P., Hatcher J.P., Bountra C., Michel A.D., Hughes J.P., Green P., Egerton J., Murfin M., Richardson J., Peck W.L., Grahames C.B., Casula M.A., Yiangou Y., Birch R., Anand P., Buell G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114:386-396.
7. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
8. Collier H.O., James G.W., Schneider C. Antagonism by aspirin and fenamates of bronchoconstriction and nociception induced by adenosine-5'-triphosphate. Nature 1966, 212:411-412.
9. Davies A., Buchanan A., Zeppetella G., Porta-Sales J., Likar R., Weismayr W., Slama O., Korhonen T., Filbet M., Poulain P., Mystakidou K., Ardavanis A., O'Brien T., Wilkinson P., Caraceni A., Zucco F., Zuurmond W., Andersen S., Damkier A., Vejlgaard T., Nauck F., Radbruch L., Sjolund K.F., Stenberg M. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013, 46:619-628.
10. Dickenson A.H., Sullivan A.F. Electrophysiological studies on the effects of intrathecal morphine on nociceptive neurones in the rat dorsal horn. Pain 1986, 24:211-222.
11. Dixon W.J. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980, 20:441-462.
12. Duan S., Anderson C.M., Keung E.C., Chen Y., Chen Y., Swanson R.A. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 2003, 23:1320-1328.
13. Ducourneau V.R., Dolique T., Hachem-Delaunay S., Miraucourt L.S., Amadio A., Blaszczyk L., Jacquot F., Ly J., Devoize L., Oliet S.H., Dallel R., Mothet J.P., Nagy F., Fenelon V.S., Voisin D.L. Cancer pain is not necessarily correlated with spinal overexpression of reactive glia markers. Pain 2014, 155:275-291.
14. Falk S., Dickenson A.H. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 2014, 32:1647-1654.
15. Falk S., Patel R., Heegaard A., Mercadante S., Dickenson A.H. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach. Eur J Pain 2014, 19:152-158.
16. Falk S., Uldall M., Heegaard A.M. The role of purinergic receptors in cancer-induced bone pain. J Osteoporos 2012, 2012:758181.
17. Gilchrist L.S., Cain D.M., Harding-Rose C., Kov A.N., Wendelschafer-Crabb G., Kennedy W.R., Simone D.A. Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Res 2005, 1044:197-205.
18. Gwak Y.S., Kang J., Unabia G.C., Hulsebosch C.E. Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol 2012, 234:362-372.
19. Hansen R.R., Malcangio M. Astrocytes-multitaskers in chronic pain. Eur J Pharmacol 2013, 716:120-128.
20. Hansen R.R., Nielsen C.K., Nasser A., Thomsen S.I., Eghorn L.F., Pham Y., Schulenburg C., Syberg S., Ding M., Stojilkovic S.S., Jorgensen N.R., Heegaard A.M. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 2011, 152:1766-1776.
21. Honore P., Donnelly-Roberts D., Namovic M., Zhong C., Wade C., Chandran P., Zhu C., Carroll W., Perez-Medrano A., Iwakura Y., Jarvis M.F. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res 2009, 204:77-81.
22. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
23. Huang Z.X., Lu Z.J., Ma W.Q., Wu F.X., Zhang Y.Q., Yu W.F., Zhao Z.Q. Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation. Pain 2014, 155:783-791.
24. Jimenez Andrade J.M., Mantyh P. Cancer pain: from the development of mouse models to human clinical trials. Translational pain research: from mouse to man 2010, Boca Raton, FL. L. Kruger, A.R. Light (Eds.).
25. Mantyh P.W., Clohisy D.R., Koltzenburg M., Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2:201-209.
26. McGaraughty S., Chu K.L., Namovic M.T., Donnelly-Roberts D.L., Harris R.R., Zhang X.F., Shieh C.C., Wismer C.T., Zhu C.Z., Gauvin D.M., Fabiyi A.C., Honore P., Gregg R.J., Kort M.E., Nelson D.W., Carroll W.A., Marsh K., Faltynek C.R., Jarvis M.F. P2X7-related modulation of pathological nociception in rats. Neuroscience 2007, 146:1817-1828.
27. Medhurst S.J., Walker K., Bowes M., Kidd B.L., Glatt M., Muller M., Hattenberger M., Vaxelaire J., O'Reilly T., Wotherspoon G., Winter J., Green J., Urban L. A rat model of bone cancer pain. Pain 2002, 96:129-140.
28. Meuser T., Pietruck C., Radbruch L., Stute P., Lehmann K.A., Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93:247-257.
29. Middlemiss T., Laird B.J., Fallon M.T. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol) 2011, 23:387-392.
30. Monif M., Burnstock G., Williams D.A. Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol 2010, 42:1753-1756.
31. Nicke A., Kuan Y.H., Masin M., Rettinger J., Marquez-Klaka B., Bender O., Gorecki D.C., Murrell-Lagnado R.D., Soto F. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 2009, 284:25813-25822.
32. Oatway M.A., Chen Y., Weaver L.C. The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 2004, 110:259-268.
33. Perez-Medrano A., Donnelly-Roberts D.L., Florjancic A.S., Nelson D.W., Li T., Namovic M.T., Peddi S., Faltynek C.R., Jarvis M.F., Carroll W.A. Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists. Bioorg Med Chem Lett 2011, 21:3297-3300.
34. Sabino M.A., Luger N.M., Mach D.B., Rogers S.D., Schwei M.J., Mantyh P.W. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 2003, 104:550-558.
35. Schmidt B.L., Hamamoto D.T., Simone D.A., Wilcox G.L. Mechanism of cancer pain. Mol Interv 2010, 10:164-178.
36. Sikandar S., Ronga I., Iannetti G.D., Dickenson A.H. Neural coding of nociceptive stimuli-from rat spinal neurones to human perception. Pain 2013, 154:1263-1273.
37. Sorge R.E., Trang T., Dorfman R., Smith S.B., Beggs S., Ritchie J., Austin J.S., Zaykin D.V., Vander Meulen H., Costigan M., Herbert T.A., Yarkoni-Abitbul M., Tichauer D., Livneh J., Gershon E., Zheng M., Tan K., John S.L., Slade G.D., Jordan J., Woolf C.J., Peltz G., Maixner W., Diatchenko L., Seltzer Z., Salter M.W., Mogil J.S. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 2012, 18:595-599.
38. Stromgren A.S., Sjogren P., Goldschmidt D., Petersen M.A., Pedersen L., Groenvold M. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 2006, 31:199-206.
39. Suzuki T., Hide I., Ido K., Kohsaka S., Inoue K., Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci 2004, 24:1-7.
40. Svendsen K.B., Andersen S., Arnason S., Arner S., Breivik H., Heiskanen T., Kalso E., Kongsgaard U.E., Sjogren P., Strang P., Bach F.W., Jensen T.S. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005, 9:195-206.
41. Takenouchi T., Sugama S., Iwamaru Y., Hashimoto M., Kitani H. Modulation of the ATP-induced release and processing of IL-1beta in microglial cells. Crit Rev Immunol 2009, 29:335-345.
42. Urch C.E., Donovan-Rodriguez T., Dickenson A.H. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 2003, 106:347-356.
43. Urch C.E., Donovan-Rodriguez T., Gordon-Williams R., Bee L.A., Dickenson A.H. Efficacy of chronic morphine in a rat model of cancer-induced bone pain: behavior and in dorsal horn pathophysiology. J Pain 2005, 6:837-845.
44. Xu J., Chu K.L., Brederson J.D., Jarvis M.F., McGaraughty S. Spontaneous firing and evoked responses of spinal nociceptive neurons are attenuated by blockade of P2X3 and P2X2/3 receptors in inflamed rats. J Neurosci Res 2012, 90:1597-1606.
45. Zhang R.X., Liu B., Wang L., Ren K., Qiao J.T., Berman B.M., Lao L. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005, 118:125-136.
46. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.